Your browser doesn't support javascript.
loading
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou, Apostolia M; Guenther, Kerstin; Andersson, Borje S; Mendrzyk, Regina; Alpert, Amir; Wagner, Claudia; Nowak, Anna; Aslan, Katrin; Satelli, Arun; Richter, Fabian; Kuttruff-Coqui, Sabrina; Schoor, Oliver; Fritsche, Jens; Coughlin, Zoe; Mohamed, Ali S; Sieger, Kerry; Norris, Becky; Ort, Rita; Beck, Jennifer; Vo, Henry Hiep; Hoffgaard, Franziska; Ruh, Manuel; Backert, Linus; Wistuba, Ignacio I; Fuhrmann, David; Ibrahim, Nuhad K; Morris, Van Karlyle; Kee, Bryan K; Halperin, Daniel M; Nogueras-Gonzalez, Graciela M; Kebriaei, Partow; Shpall, Elizabeth J; Vining, David; Hwu, Patrick; Singh, Harpreet; Reinhardt, Carsten; Britten, Cedrik M; Hilf, Norbert; Weinschenk, Toni; Maurer, Dominik; Walter, Steffen.
Afiliación
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Guenther K; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Andersson BS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mendrzyk R; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Alpert A; Immatics US, Inc., Houston, Texas.
  • Wagner C; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Nowak A; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Aslan K; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Satelli A; Immatics US, Inc., Houston, Texas.
  • Richter F; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Kuttruff-Coqui S; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Schoor O; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Fritsche J; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Coughlin Z; Immatics US, Inc., Houston, Texas.
  • Mohamed AS; Immatics US, Inc., Houston, Texas.
  • Sieger K; Immatics US, Inc., Houston, Texas.
  • Norris B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ort R; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Beck J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vo HH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hoffgaard F; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Ruh M; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Backert L; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fuhrmann D; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas.
  • Kee BK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas.
  • Halperin DM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas.
  • Nogueras-Gonzalez GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vining D; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Singh H; Immatics N.V., Tuebingen, Germany.
  • Reinhardt C; Immatics N.V., Tuebingen, Germany.
  • Britten CM; Immatics N.V., Tuebingen, Germany.
  • Hilf N; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Weinschenk T; Immatics N.V., Tuebingen, Germany.
  • Maurer D; Immatics Biotechnologies GmbH, Tuebingen, Germany.
  • Walter S; Immatics US, Inc., Houston, Texas.
Cancer Immunol Res ; 11(7): 925-945, 2023 07 05.
Article en En | MEDLINE | ID: mdl-37172100
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Neoplasias Tipo de estudio: Etiology_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Cancer Immunol Res Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Neoplasias Tipo de estudio: Etiology_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Cancer Immunol Res Año: 2023 Tipo del documento: Article